Clinical data from the ITN’s ACCESS study (Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis) will be presented at two upcoming conferences. The ACCESS study examined whether the combination of abatacept (CTLA4-Ig) and cyclophosphamide is able to better induce tolerance compared to the Euro-Lupus regimen (low-dose pulse cyclophosphamide).
David Wofsy, MD (University of California, San Francisco), one of the ACCESS study Co-Chairs, will present the 52-week results in an oral abstract at the annual American College of Rheumatology (ACR) meeting in San Diego, CA on Sunday, October 27th at 5:30pm PT.
Brad Rovin, MD (Ohio State University), a site investigator, will also present the 52-week data at the American Society of Nephrology’s (ASN) Kidney Week 2013 in Atlanta, GA on November 5-10. The results of this study are of great interest to both the rheumatology and nephrology communities.
For more information about the ACCESS trial, see here.